摘要
The proportion of liver transplantation(LT)for hepatocellular carcinoma(HCC)has kept on increasing over the past years and account for 20%-40%of all LT.Post-transplant HCC recurrence is considered the most important factor affecting the long-term survival of patients.The use of different types of immunosuppressive agents after LT is closely associated with an increased risk for HCC recurrence.The most commonly used conventional immunosuppressive drugs include the calcineurin inhibitors tacrolimus(FK506)and mammalian target of rapamycin inhibitor rapamycin(RAPA).Compared with tacrolimus,RAPA may carry an advantage in survival benefit because of its anti-tumor effects.However,no sufficient evidence to date has proven that RAPA could increase long-term recurrence-free survival and its anti-tumor mechanism of combined therapy remains incompletely clear.In this review,we will focus on recent advances in clinical application experience and basic research results of RAPA in patients undergoing LT for HCC to further guide the clinical practice.
